Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CVKD Catalyst Timeline
Dated clinical, regulatory and corporate events for Cadrenal Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cadrenal Therapeutics, Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How CVKD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-11 | CAD-1005 | Phase 2 data presentation | Phase 2 |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VLX-1005 Small MoleculesCompletedNCT05325346 | Heparin-induced Thrombocytopenia | Phase 1 | COMPLETED | 12 | Apr 14, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every CVKD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CAD-1005 Fast TrackOrphan | Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) | Phase 2 | 2026-08-03 | greater than 25%Read More | Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 DiscontinuationRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Pham Quang XDirector, Officer (Chairman and CEO), 10% Owner | Sell | -7,400 98,589 held | $3.03 | 06/29/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CVKD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CVKD for Q3 2026. | ||||
Ownership Trends
CVKD Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How CVKD ranks across every disease it competes in
CVKD News
Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
Cadrenal Therapeutics has initiated a formal strategic process to explore opportunities for maximizing the value of its assets, including CAD-1005, following alignment with the FDA on its Phase 3 development pathway. The company has engaged Tungsten Advisors as its exclusive financial advisor and has received significant interest from potential partners. However, there is no guarantee that this process will result in any transactions.
Read more →Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
Cadrenal Therapeutics, Inc. will participate in the Lytham Partners Fall 2026 Investor Conference on September 29-30, 2026. CEO Quang X. Pham will present via webcast and hold one-on-one meetings with investors. The company focuses on therapies for critical care cardiology and has a promising pipeline, including CAD-1005 and tecarfarin, both of which have received FDA designations.
Read more →Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
Cadrenal Therapeutics, Inc. will participate in the 28th Annual H.C. Wainwright Global Investment Conference from September 14-16, 2026. CEO Quang X. Pham will present on the company's Cardiac Acute Critical Care Franchise and recent Phase 2 clinical data for CAD-1005. A pre-recorded presentation will be available starting September 11, 2026.
Read more →Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
Cadrenal Therapeutics received positive feedback from the FDA during a Type D meeting regarding the Phase 3 registration study of CAD-1005 for treating heparin-induced thrombocytopenia (HIT). The FDA agreed on the primary endpoint and statistical analysis plan, which aims to evaluate the drug's effectiveness in reducing thrombotic events. CAD-1005 is positioned to target an unmet need in a significant patient population, with a projected revenue opportunity of $2 billion.
Read more →Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
Cadrenal Therapeutics reported its Q2 2026 financial results and updates on its Cardiac Acute Critical Care Franchise. The company achieved regulatory guidance for CAD-1005's Phase 3 path and presented promising Phase 2 data at an international congress. Cadrenal is pursuing a structured partnering process to enhance its portfolio and address unmet needs in critical care cardiology.
Read more →Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation
Cadrenal Therapeutics has consolidated its strategy for CAD-1005, targeting both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). This move follows the discontinuation of a competitor's Phase 3 trial, highlighting the urgent need for novel treatments in this area. CAD-1005 has shown promising clinical data, positioning it as a first-in-class therapy in a lucrative market.
Read more →Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
Cadrenal Therapeutics has initiated a partnering process for its cardiac acute critical care assets, including CAD-1005, frunexian, and tecarfarin. The company aims to secure strategic partnerships for these late-stage therapies following positive Phase 2 data presented at the ISTH 2026 Congress. This strategic alignment is designed to maximize asset value and address unmet needs in critical care cardiology.
Read more →Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
Cadrenal Therapeutics presented late-breaking Phase 2 data for CAD-1005 at the ISTH 2026 Congress, showing over a 25% reduction in thrombotic events in patients with Heparin-Induced Thrombocytopenia (HIT). This trial is notable as the first randomized, blinded, placebo-controlled study in this area. The results support the advancement of CAD-1005 towards Phase 3 trials, addressing a significant medical need.
Read more →Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Cadrenal Therapeutics has announced a private placement of up to $8.8 million, with $3 million upfront and potential additional proceeds from warrants. The funds are expected to extend the company's cash runway into 2027, allowing for the advancement of therapies for Kawasaki Disease and other conditions. The offering is set to close on July 1, 2026, pending customary conditions.
Read more →Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress
Cadrenal Therapeutics announced that its Phase 2 study of CAD-1005 has been selected for a late-breaking oral presentation at the ISTH 2026 Congress. This trial is the first randomized, blinded, placebo-controlled study for Heparin-Induced Thrombocytopenia (HIT), a serious blood-clotting disorder. The presentation will highlight the clinical potential of CAD-1005, a novel 12-lipoxygenase inhibitor, which could transform treatment for HIT patients.
Read more →Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
Cadrenal Therapeutics is preparing to file for a Rare Pediatric Disease Designation for tecarfarin, aimed at treating Kawasaki disease in children. This designation could lead to a Priority Review Voucher, enhancing the drug's market potential. The company will showcase its initiatives at the upcoming BIO International Convention, highlighting its Phase 3-ready pipeline.
Read more →Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
Cadrenal Therapeutics announced plans to initiate a Phase 2a clinical trial for CAD-1005, targeting Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). This indication expands the drug's potential market, estimated at $1 billion annually, as there are currently no FDA-approved therapies for CSA-AKI. The trial aims to generate safety and efficacy data while leveraging existing research on CAD-1005's use in heparin-induced thrombocytopenia (HIT). Discussions about this strategy will take place at the upcoming BIO 2026 conference.
Read more →Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
Cadrenal Therapeutics is set to showcase its Phase 3-ready CAD-1005 and 12-LOX platform at the BIO International Convention 2026. CAD-1005 targets Heparin-Induced Thrombocytopenia (HIT) and has received FDA designations for its potential to address unmet medical needs. The company aims to explore broader applications for its 12-LOX inhibitor platform, which may impact various inflammatory diseases. Tecarfarin, another late-stage product, is designed for patients with complex anticoagulation needs.
Read more →Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Cadrenal Therapeutics, Inc. will participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026. The company will host a webcast presentation and one-on-one meetings with investors. Cadrenal is focused on developing therapies for immune and thrombotic conditions, including its lead program CAD-1005, which targets heparin-induced thrombocytopenia.
Read more →Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
Cadrenal Therapeutics reported its financial results for the first quarter of 2026 and updated on the development of CAD-1005, a treatment for heparin-induced thrombocytopenia (HIT). The company has received FDA guidance following their End-of-Phase 2 meeting, which outlines the path for a pivotal Phase 3 trial. Cadrenal plans to move directly to a randomized, placebo-controlled study, building confidence that CAD-1005 could become the first new therapy for HIT in over 20 years. Financially, the company experienced reduced operating expenses but reported a net loss of $2.5 million.
Read more →Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
Cadrenal Therapeutics has announced a significant regulatory milestone following its successful End-of-Phase 2 meeting with the FDA regarding CAD-1005, aimed at treating heparin-induced thrombocytopenia (HIT). The FDA provided essential guidance for Cadrenal's plan to move forward with a pivotal Phase 3 registration study, which will evaluate CAD-1005 in around 120 patients globally. The Phase 3 study intends to support a new drug application by 2029, marking CAD-1005 as a potential groundbreaking therapy for HIT, which has not seen new treatment options in decades.
Read more →Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
Cadrenal Therapeutics has reported its fourth quarter 2025 financial results along with an update on its CAD-1005 program for heparin-induced thrombocytopenia (HIT). The company revealed that encouraging Phase 2 data supports continued development of CAD-1005 as a priority, following a successful End-of-Phase 2 meeting with the FDA. Although the company is experiencing financial losses, the progress in clinical development and FDA collaboration signifies potential advancements in treatment for HIT.
Read more →Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing
Cadrenal Therapeutics has announced promising research highlighting the potential of its first-in-class 12-lipoxygenase (12-LOX) inhibitor, CAD-1005, in reducing inflammation associated with obesity and Type 2 diabetes. The findings suggest that 12-LOX inhibition may improve glucose homeostasis and peripheral inflammation. Additionally, CAD-1005 has shown significant benefits in preclinical models and has been successful in a Phase 2 trial for treating Heparin-Induced Thrombocytopenia (HIT). The company aims to explore further applications of 12-LOX inhibition in various inflammatory conditions.
Read more →Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
Cadrenal Therapeutics announced promising results from a Phase 2 study of CAD-1005, a selective 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT). The company plans to hold an End-of-Phase 2 meeting with the FDA soon. Additionally, the acquisition of a 12-LOX inhibitor portfolio opens avenues for treating various inflammatory and thrombotic conditions, potentially addressing significant market needs.
Read more →Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
Cadrenal Therapeutics announced positive Phase 2 trial results for CAD-1005 in patients with heparin-induced thrombocytopenia (HIT), showing a greater than 25% reduction in thrombotic events compared to placebo. Although the primary endpoint of platelet count recovery was not met, the secondary endpoint results were encouraging. An End-of-Phase 2 meeting with the FDA is scheduled to discuss the path forward for Phase 3 trials.
Read more →